You are here

Articles

NCCN 2020 QUICK GUIDE - Guidelines for CML Patients

published: 28 February 2020

Update: An investigation into the use of app technology in patients with CML

published: 19 February 2020

Managing CML for treatment-free remission (TFR): A proposal - GIMEMA CML WP

published: 3 February 2020

Ruxolitinib Shows Noteworthy Responses in Patients with Atypical CML

published: 14 January 2020

Do persons with chronic myeloid leukaemia have normal or near normal survival?

published: 6 January 2020

An investigation into the use of app technology in patients with CML.

published: 5 November 2019

Cessation of nilotinib in patients with CML who have kept deep molecular responses for 2yrs

published: 3 October 2019

Combining Asciminib with Ponatinib Suppresses Emergence Highly Resistant BCR-ABL1 Mutants

published: 3 October 2019

Long‐term follow‐up of lower dose dasatinib (50 mg daily) as frontline therapy in newly diagnosed chronic CML

published: 3 October 2019

CML: the concepts of resistance and persistence and the relationship with BCR-ABL1

published: 3 October 2019

Cortes Highlights Second-Generation TKIs for Frontline Therapy in CML

published: 9 August 2019

Video Recordings: UK Chronic Myeloid Leukaemia Patient Day 2019

published: 15 July 2019

CML Horizons 2019 Presentations and Video streams are available now!

published: 6 July 2019

King's College London - Patient Group (July 24th)

published: 29 June 2019

De-Escalation of TKI Therapy Before Complete Treatment Discontinuation in Patients With CML

published: 26 June 2019

CML Horizons Conference Report: Lisbon Portugal May 17th - 19th 2019

published: 28 May 2019

Early results of lower dose dasatinib (50 mg daily) as frontline therapy

published: 22 May 2019

TKI Discontinuation Criteria Established in Updated NCCN Guidelines

published: 27 March 2019

Skeletal muscle toxicity associated with TKIs in CML patients

published: 18 March 2019

Falsified Iclusig / ponatinib traded globally

published: 31 January 2019